AKIR001 is a high-affinity human IgG1 antibody targeting CD44v6. AKIR001 carries LALA-silencing mutations in its FcγR-binding domain to reduce FcγR and C1q interactions, minimizing tissue interactions and limiting CDC and ADCC risks. [ 177 Lu] radiolabeled AKIR001, namely [ 177 Lu]Lu-AKIR001, has anticancer activity against epidermoid carcinoma [1].
In Vivo, [177Lu]Lu-AKIR001 (5-15 MBq) exhibits dose-dependent efficacy in female BALB/c nu/nu mice with A431 cell xenograft (with complete response rates of 75-80%)[1].
In Vitro, AKIR001 lacks CDC and ADCC activity in BxPC-3 cells[1].
References:
[1]. Mortensen ACL, et al. Preclinical Validation of [ 177 Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials. J Nucl Med. Published online November 6, 2025.
In Vivo, [177Lu]Lu-AKIR001 (5-15 MBq) exhibits dose-dependent efficacy in female BALB/c nu/nu mice with A431 cell xenograft (with complete response rates of 75-80%)[1].
In Vitro, AKIR001 lacks CDC and ADCC activity in BxPC-3 cells[1].
References:
[1]. Mortensen ACL, et al. Preclinical Validation of [ 177 Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials. J Nucl Med. Published online November 6, 2025.